Low-dose aspirin mitigates liver cancer risk: Study

New Delhi, Mar 14 (ANI): Among adults at high risk of liver cancer, those who took low-dose aspirin were less likely to develop the disease or to die from liver-related causes. The findings come from an analysis published in the New England Journal of Medicine and conducted by a team led by investigators at the Karolinska Institutet, in Sweden, and Massachusetts General Hospital (MGH). For the analysis, investigators examined information from Swedish registries on 50,275 adults who had chronic viral hepatitis, a type of liver infection that is caused by the hepatitis B or C virus and is the most common risk factor for liver cancer. Over a median follow-up of nearly 8 years, 4.0% of patients who took low-dose aspirin (less than 163mg/day) and 8.3% of nonusers of aspirin developed liver cancer. Aspirin users had a 31% lower relative risk of developing liver cancer. Importantly, the study showed that the longer a person took low-dose aspirin, the greater the benefit. Compared with short-t